Noble Biomaterials, Inc.

Noble Biomaterials, Inc. develops advanced intelligent materials, focusing on innovative solutions that enhance performance in diverse applications, including healthcare, industrial, and defense sectors. Founded in 1997 and headquartered in Scranton, US, Noble Biomaterials specializes in intelligent materials. The firm has undergone strategic pivots to expand its product lines.

Joel Furey is the founder, and the company has secured a total of USD 8. 00 mn through various funding rounds, with the latest being a Series B round led by Northwater Capital Management on July 1, 2013. Noble Biomaterials specializes in advanced intelligent materials, with a primary focus on innovative product offerings such as Circuitex®, Ionic+®, and X-Static®. These materials are engineered to enhance performance across a range of applications, including energy management, health and medical sectors, and aerospace and defense.

Circuitex® serves as a comprehensive energy material that promotes efficient energy harvesting and storage, while Ionic+® provides antimicrobial properties suitable for textiles and medical applications. X-Static®, recognized for its unique silver-based technology, is utilized in performance fabrics to offer odor control and moisture management. The company caters to a diverse client base, including manufacturers in the healthcare, industrial, and consumer goods sectors, with products distributed widely across North America, Europe, and Asia. Noble Biomaterials generates revenue through a B2B model, engaging primarily with manufacturers and industry partners who incorporate their intelligent materials into consumer products.

Transactions typically occur through direct partnerships and supply agreements, enabling clients to utilize Noble's proprietary technologies in their offerings. Pricing structures are established based on contracts that reflect the value and performance benefits of each material, particularly for flagship products such as X-Static® and Circuitex®. These agreements may involve bulk purchasing arrangements or licensing fees, tailored to meet the specific needs of diverse industries. This strategic approach ensures a consistent revenue stream while fostering long-term relationships with clients across various geographical markets.

Noble Biomaterials plans to introduce new products designed to enhance their existing offerings, although specific release dates have not been disclosed. The company is targeting expansion into key markets in Asia and Europe by 2025 to tap into growing demand in those regions. Recent Series C funding of USD 8. 00 mn is expected to support these initiatives, enhancing research and development efforts for new product launches and market entry strategies.